Inmune Bio Secures ~$0.9M Cash from Warrant Exercise, Extends Remaining Warrants to 2027
INMB sits 53% above its 52-week low of $1.09.
Summary
Inmune Bio raised approximately $0.9 million by inducing warrant holders to exercise 50% of their April 2024 warrants at a reduced price of $1.40 per share. The remaining 50% of those warrants had their maturity extended from June 2026 to December 2027. This follows an 8-K filed earlier today disclosing the same event. This capital infusion, while modest, provides immediate cash to support operations for a company that had previously issued a going concern warning due to liquidity issues. The warrant extension also offers longer-term financing flexibility.
At the time of this announcement, INMB was trading at $1.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $43.3M. The 52-week trading range was $1.09 to $3.24. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.